Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Alena, Gros"'
Autor:
Sandra García-Mulero, Roberto Fornelino, Marco Punta, Stefano Lise, Mar Varela, Luis P. del Carpio, Rafael Moreno, Marcel Costa-García, Dietmar Rieder, Zlatko Trajanoski, Alena Gros, Ramón Alemany, Josep María Piulats, Rebeca Sanz-Pamplona
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTUveal melanoma (UM) is the most common ocular malignancy in adults. Nearly 95% of UM patients carry the mutually exclusive mutations in the homologous genes GNAQ (amino acid change Q209L/Q209P) and GNA11 (aminoacid change Q209L). UM is locate
Externí odkaz:
https://doaj.org/article/623ba2cd7fe440f08b80ee759bb43d1a
Autor:
Xavier Matias-Guiu, Ana Vivancos, Jordi Ponce, Ignacio Melero, Alena Gros, Josep María Piulats, Carlos E De Andrea, Maria Lozano-Rabella, Jara Palomero, August Vidal, Carla Panisello, Ricky Tirtakasuma, Judit Díaz-Gómez, Daniela Grases, Helena Pasamar, Laura Arregui, Eduard Dorca Duch, Esther Guerra Fernández
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Despite the growing interest in immunotherapeutic interventions for endometrial cancer (EC), the prevalence, phenotype, specificity and prognostic value of tumor infiltrating lymphocytes (TILs) in this tumor type remains unclear.Methods To
Externí odkaz:
https://doaj.org/article/a6c6008c42274bd88a20c1988684f4bb
Autor:
Enrique J. Arenas, Alex Martínez-Sabadell, Irene Rius Ruiz, Macarena Román Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquín Arribas
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Several mechanisms of resistance to T cell-engaging therapies have been described for solid tumors. Here, by using T cell bispecific antibodies and chimeric antigen receptors (CAR) T cells targeting HER2, the authors show that cancer cell intrinsic d
Externí odkaz:
https://doaj.org/article/aa94e03a034246f68048ebc589ddfa65
Autor:
Xavier Matias-Guiu, Alena Gros, Jared Gartner, Steven Rosenberg, Juan Martin-Liberal, Josep María Piulats, Elena Garralda, Florian Erhard, Andreas Schlosser, Irene Brana, Eva Muñoz, Maria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, Ignacio Matos, Michael Ghosh, Francesc Canals, August Vidal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6f8b6289045e47ccb565648afe904243
Autor:
Nuria Chic, Eva Ciruelos, Cristina Saura, Europa-Azucena Gonzalez, Luís Álvarez-Vallina, Juan José Lasarte, Alena Gros, Lorea Villanueva, Jordi Canes, Laura Angelats, Aleix Prat, Tomás Pascual, Marta Santisteban, Manel Juan
Publikováno v:
Cancer Research. 83:OT2-10
Background Metastatic triple-negative breast cancer (mTNBC) exhibits a particularly poor clinical outcome, generally with rapid progression and worse overall survival (OS) than other BC subtypes. Among the few therapeutic options, chemotherapy-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70648c1f7175177653a5518d029346a9
https://doi.org/10.1158/1538-7445.sabcs22-ot2-10-04
https://doi.org/10.1158/1538-7445.sabcs22-ot2-10-04
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Based on the success of tumor-infiltrating lymphocytes (TIL)-based therapies, personalized adoptive cell therapies (ACT) targeting neoantigens have the potential to become a disruptive technology and lead to highly effective treatments for cancer pat
Externí odkaz:
https://doaj.org/article/e35d59547b204fe29fac1882703dfb2d
Autor:
Maria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Roc Farriol-Duran, Juan Martín-Liberal, Maria Ochoa-de-Olza, Ignacio Matos, Jared J. Gartner, Michael Ghosh, Francesc Canals, August Vidal, Josep Maria Piulats, Xavier Matías-Guiu, Irene Brana, Eva Muñoz-Couselo, Elena Garralda, Andreas Schlosser, Alena Gros
Publikováno v:
Scientia
Immunogenicity; Proteogenomics Inmunogenicidad; Proteogenómica Immunogenicitat; Proteogenòmica Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe8c7b8c02cd12225ff5cd0e3f083be
https://hdl.handle.net/11351/9824
https://hdl.handle.net/11351/9824
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
All tumors accumulate genetic alterations, some of which can give rise to mutated, non-self peptides presented by human leukocyte antigen (HLA) molecules and elicit T-cell responses. These immunogenic mutated peptides, or neoantigens, are foreign in
Externí odkaz:
https://doaj.org/article/8b0bc3b23ce040089b9271a7bab9b011
Autor:
Steven A. Rosenberg, Jessica S. Crystal, Katarzyna Trebska-McGowan, Jared Gartner, Maria R. Parkhurst, Harlan Robins, Bryan Howie, Daniel C. Douek, Rodrigo Matus-Nicodemos, Todd D. Prickett, Drew C. Deniger, Paul F. Robbins, Alena Gros, Anna Pasetto
Gating strategy, Shannon entropy, PD-1 expression, additional co-culture data, primers sequence, Frequency of the top 10 CD8+PD-1+ TCRB in bulk unsorted TIL and sorted TIL subsets, Retrospective analysis of pairing the most frequent TCRB in the CD8+P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18367889110460b48bb9bc005e4ef135
https://doi.org/10.1158/2326-6066.22537856.v1
https://doi.org/10.1158/2326-6066.22537856.v1
Autor:
Nicholas P. Restifo, Rahul Roychoudhuri, Marcus W. Bosenberg, Mark Raffeld, Chyi-Chia R. Lee, David F. Stroncek, Francesco Marincola, Ena Wang, Hui Liu, Luca Gattinoni, Zulmarie Franco, James J. Morrow, Madhusudhanan Sukumar, Joseph G. Crompton, Christopher A. Klebanoff, Gautam U. Mehta, Ian S. Goldlust, Ken-ichi Hanada, Alena Gros, Yun Ji, Holger Pflicke, Liqiang Xi, Douglas C. Palmer, Melody Roelke-Parker, Zhiya Yu, David Clever, Nicolas Acquavella
Fig. S1. Establishment of SB-3123 murine melanoma model. Fig. S2. Schematic of primer design for BRAF c.1799T > A (V600E) mutation analysis in SB-3123p murine melanoma cells. Fig. S3. SB-3123p melanoma is highly sensitive to vemurafenib. Fig. S4. BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2f934c744af33f0ef1e95415e86aa9
https://doi.org/10.1158/2326-6066.22537816.v1
https://doi.org/10.1158/2326-6066.22537816.v1